<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2904</article-id>
         <article-id pub-id-type="publisher-id">2904</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Metabolne in hormonske motnje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Izvirni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Metabolne in hormonske motnje</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Opazovalna raziskava odraslih bolnikov z neurejeno astmo v zunajbolnišničnih pnevmoloških ambulantah po Sloveniji</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Observational study of adult patients with uncontrolled asthma in pneumology outpatients clinics in Slovenia</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Opazovalna raziskava odraslih bolnikov z neurejeno astmo</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Kajba</surname>
                  <given-names>Stanislav</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Specialistična pnevmološka ambulanta, Zdravstveni dom Celje, Celje, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Pulmonary Department, Community health centre, Celje, Slovenia </institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Stanislav Kajba, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>10</month>
            <year>2019</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>10</month>
            <year>2019</year>
         </pub-date>
         <volume>88</volume>
         <issue>9–10</issue>
         <fpage>415</fpage>
         <lpage>26</lpage>
         <history>
            <date date-type="received">
               <day>11</day>
               <month>12</month>
               <year>2018</year>
            </date>
            <date date-type="accepted">
               <day>18</day>
               <month>7</month>
               <year>2019</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2019</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Izhodišče: Skoraj 50 % bolnikov z astmo ima v klinični praksi kljub zdravljenju po merilih GINA (Global Initiative for Asthma) neurejeno bolezen. Najpogostejši vzroki neurejene astme so: nepravilna uporaba vdihovalnika, slabo sodelovanje bolnika, nepravilna diagnoza astme, pridružene bolezni (rinosinuzitis, GERB (gastroezofagealna refluksna bolezen), debelost, depresija, obstruktivna nočna apneja) in tudi stalna izpostavljenost specifičnim sprožilcem astme (alergeni, zdravila in kajenje).</p>
            <p>Metode: Med 323 bolniki z neurejeno astmo v 14 zunajbolnišničnih pnevmoloških ambulantah je med decembrom 2017 in aprilom 2018 potekala opazovalna raziskava. Raziskovalci so v svojih ambulantah vnašali podatke o najpogostejših vzrokih za neurejeno astmo in hudih poslabšanjih v zadnjem letu v elektronski sistem za zbiranje podatkov.</p>
            <p>Rezultati: Najpogostejši dejavniki, povezani z neurejeno astmo, so bile pridružene bolezni v 70 % (debelost 33 %, rinosinusitis 28 %, GERB 22 %), specifični sprožilci v 56 % (izpostavljenost alergenom 39 %, zdravila 35 %, kajenje 10 %) in slabo sodelovanje bolnikov v 53 %. Trideset odstotkov bolnikov je imelo vsaj eno hudo poslabšanje v zadnjem letu. Logistična regresijska analiza je pokazala, da sta nerazumevanje vloge zdravil (95 % IZ: [1,4; 4,8]; p = 0019) in odsotnost individualiziranega načrta samozdravljenja (95 %IZ:[1,3; 4,3]; p = 0,042) najpomembnejša vzroka za huda poslabšanja. Težko astmo po merilih GINA je imelo 23 % bolnikov, vključenih v raziskavo.</p>
            <p>Zaključek: Najpogostejši dejavniki, ki so povezani z neurejeno astmo pri vzorčni populaciji odraslih bolnikov z neurejeno astmo v zunajbolnišničnih pnevmoloških ambulantah po Sloveniji, so pridružene bolezni, specifični sprožilci in slaba adherenca bolnikov. Ti bolniki imajo še vedno huda poslabšanja. V prihodnosti bo potrebno bolnike z astmo še bolje izobraziti in jih vse oskrbeti z individualiziranim načrtom samozdravljenja astme.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Almost 50 % of patients in clinical practice still have poor control of their asthma despite treatment according to the GINA (Global Initiative for Asthma) criteria. The most common causes of uncontrolled asthma are: poor inhaler technique, poor medication adherence, incorrect diagnosis, comorbidities (rhinosinusitis, GERD (Gastroesophageal Reflux Disease), obesity, depression, obstructive sleep apnea) and ongoing exposure to specific triggers (allergens, drugs and smoking).</p>
            <p>Methods: Observational study was conducted on 323 adult patients with uncontrolled asthma in 14 outpatient pulmonology practices in Slovenia in the period from December 2017 to April 2018. Data about common causes of uncontrolled asthma and exacerbations in the last year were entered in electronic case report forms at the investigator`s site.</p>
            <p>Results: The most common factors associated with uncontrolled asthma were comorbidities in 70 % (obesity 33 %, rhinosinusitis 28 %, GERD 22 %), specific triggers in 56 % (ongoing exposure to allergens 39 %, drugs 35 %, smoking 10 %) and poor medication adherence in 53 %. Thirty percent of patients had one or more severe exacerbations in the last year. Patient’s non-understanding of the role of asthma medications (95 % IZ: [1.4; 4.8]; p = 0.019) and the lack of self-management plan (95 % IZ: [1.3; 4.3]; p = 0.042) were the most important factors in the logistic regression model for severe exacerbations. 23 % of included patients had severe asthma according to the GINA criteria.</p>
            <p>Conclusion: Obesity, specific triggers and poor medication adherence are the most important factors for uncontrolled asthma in the adult patient sample with uncontrolled asthma in pneumology outpatient clinics in Slovenia. Severe exacerbations are still present in these patients. Therefore, better education and providing all asthma patients with written self-management plan would be warranted in the future.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>neurejena astma</kwd>
            <kwd>adherenca</kwd>
            <kwd>komorbidnost</kwd>
            <kwd>specifični sprožilci</kwd>
            <kwd>hudo poslabšanje astme</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>uncontrolled asthma</kwd>
            <kwd>adherence</kwd>
            <kwd>comorbidities</kwd>
            <kwd>specific triggers</kwd>
            <kwd>severe asthma exacerbation</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Astma je pogosta kronična vnetna bolezen dihalnih poti. Cilj zdravljenja astme po smernicah GINA (Global Initiative for Asthma) je doseči nadzor nad boleznijo (<xref ref-type="bibr" rid="b1">1</xref>). Nadzor nad boleznijo vključuje nadzor simptomov in zmanjševanje tveganja za: akutna poslabšanja astme, razvoj trajne obstrukcije na dihalnih poteh in pojav lokalnih ter sistemskih stranskih učinkov zdravil. Ocena nadzora simptomov temelji na preverjanju štirih kliničnih parametrov in se nanaša na zadnje štiri tedne pred ocenjevanjem bolnika. Astma se glede na prisotnost dnevnih in nočnih simptomov, uporabo olajševalca in omejeno aktivnost bolnika opredeljuje kot urejena, delno urejena ali neurejena (<xref ref-type="table" rid="table1">Tabela 1</xref>).</p>
         <table-wrap position="anchor" id="table1" orientation="portrait">
            <label>Tabela 1:</label>
            <caption>
               <p> Ocena urejenosti astme (GINA 2018).</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Parametri urejenosti astme</th>
                     <th align="center" colspan="3" rowspan="1">Stopnja urejenosti astme</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Zadnje 4 tedne pred oceno</th>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Urejena</th>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Delno urejena</th>
                     <th content-type="table-subhead" rowspan="1" colspan="1">Neurejena</th>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>Dnevni simptomi astme</p>
                        <p>(simptomi več kot 2-krat na teden)</p>
                     </td>
                     <td rowspan="1" colspan="1">Ne</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>Nočni simptomi astme</p>
                        <p>(kadar koli v zadnjih 4 tednih)</p>
                     </td>
                     <td rowspan="1" colspan="1">Ne</td>
                     <td rowspan="1" colspan="1">1 – 2 parametra</td>
                     <td rowspan="1" colspan="1">3 – 4 parametri</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>Uporaba kratkodelujočega olajševalca</p>
                        <p>(več kot 2-krat na teden)</p>
                     </td>
                     <td rowspan="1" colspan="1">Ne</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">
                        <p>Omejitve aktivnosti zaradi astme</p>
                        <p>(kadar koli v zadnjih 4 tednih)</p>
                     </td>
                     <td rowspan="1" colspan="1">Ne</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Mednarodna raziskava REALISE (<italic toggle="yes">angl.</italic> The REcognise Asthma and LInk to Symptoms and Experience), v katero je bilo vključenih 8000 bolnikov z astmo v starosti od 18 do 50 let, je pokazala, da ima 45 % bolnikov z astmo kljub zdravljenju neurejeno bolezen. Podatke o bolnikih so pridobili z vprašalniki, poslanimi po elektronski pošti v 11 evropskih državah. Urejenost astme so ocenjevali po merilih GINA (<xref ref-type="bibr" rid="b2">2</xref>). Raziskava, izvedena v Sloveniji, je pokazala, da ima neurejeno bolezen 38 % bolnikov z astmo (<xref ref-type="bibr" rid="b3">3</xref>).</p>
         <p>Najpogostejši vzroki za neurejeno astmo so: nepravilno jemanje zdravil, slabo sodelovanje (adherenca) bolnika, nepravilna diagnoza astme, pridružene bolezni in stanja, ki zapletajo stanje, kot so rinosinuzitis, GERB (gastroezofagealna refluksna bolezen), anksioznost in depresija, debelost, obstruktivna nočna apneja, kajenje, pa tudi stalna izpostavljenost specifičnim sprožilcem astme (blokatorji beta, zaviralci angiotenzinske konvertaze, nesteroidna protivnetna zdravila ali izpostavljenost alergenom v delovnem ali domačem okolju) (<xref ref-type="bibr" rid="b1">1</xref>). Proti zdravilom odporna težka astma (<italic toggle="yes">angl.</italic> treatment-resistant severe asthma) se kot vzrok neurejene astme javlja pri manjšem deležu bolnikov. Nizozemska opazovalna raziskava je ugotovila, da je težka astma glede na merila evropskega respiratornega in ameriškega torakalnega združenja (ERS/ATS) (<xref ref-type="bibr" rid="b4">4</xref>) prisotna le pri 4,5 % bolnikov z astmo (<xref ref-type="bibr" rid="b5">5</xref>). V zadnjih letih so razvili nova biološka zdravila, ki pri delu bolnikov s težko astmo zmanjšajo število zmernih in hudih poslabšanj in zmanjšajo potrebo po zdravljenju s sistemskimi glukokortikoidi. Fenotipska opredelitev težke astme igra ključno vlogo pri izboru biološkega zdravila. Monoklonska protitelesa proti IgE (omalizumap) se uporabljajo pri zdravljenju težke alergijske astme, monoklonska protitelesa proti IL-5 (mepolizumab, reslizumab) in IL-5R (benralizumab) pa pri težki nealergijski eozinofilni astmi. Zaenkrat uspešnih bioloških zdravil za druge fenotipe težke astme še ni v klinični uporabi (<xref ref-type="bibr" rid="b6">6</xref>).</p>
         <p>V prispevku predstavljamo rezultate raziskave odraslih bolnikov z neurejeno astmo, ki so bili v petmesečnem obdobju v letih 2017 in 2018 obravnavani v zunajbolnišničnih specialističnih ambulantah po Sloveniji.</p>
         <p>Namen naše raziskave je bil poiskati najpogostejše vzroke za neurejeno astmo na vzorcu odraslih bolnikov z astmo v Sloveniji. V prispevku se tudi osredinjamo na pogostost hudih poslabšanj astme v zadnjem letu, povezavo med vzroki za neurejeno astmo in večjim številom hudih poslabšanj in oceno deleža bolnikov s težko astmo.</p>
      </sec>
      <sec id="s2" sec-type="Material in metode">
         <label>2</label>
         <title>Material in metode</title>
         <sec id="s2.1" sec-type="Preiskovanci">
            <label>2.1</label>
            <title>Preiskovanci</title>
            <p>V neintervencijski opazovalni presečni raziskavi so specialisti pulmologije oz. interne medicine vključevali odrasle bolnike z neurejeno astmo, ki so bili v obdobju od decembra 2017 do aprila 2018 obravnavani v 14 zunajbolnišničnih specialističnih ambulantah po Sloveniji. Obravnavani bolniki so bili naročeni na redno kontrolo v specialistično ambulanto ali pa so jih napotili družinski zdravniki zaradi neurejene astme. V raziskavi so lahko sodelovali le bolniki, starejši od 18 let, ki so imeli vsaj 12 mesecev klinično diagnozo astme potrjeno s pozitivnim bronhodilatacijskim testom ali pozitivnim metaholinskim provokacijskim testom (PD20 pri 2 mg metaholina ali manj). Astma je morala biti po merilih GINA neurejena (<xref ref-type="table" rid="table1">Tabela 1</xref>). Bolnik vsaj en mesec pred vključitvijo v raziskavo ni smel imeti poslabšanja astme, ki bi zahtevala spremembo vzdrževalnega zdravljenja. Izključitvena merila so bila še akutna bolezen, nosečnost in sodelovanje v kakršnem koli kliničnem preskušanju v preteklih 12 mesecih.</p>
         </sec>
         <sec id="s2.2" sec-type="Metoda dela">
            <label>2.2</label>
            <title>Metoda dela</title>
            <p>Podatki so bili zbrani iz kartotek bolnikov, na podlagi informacij, ki jih je zdravnik dobil na obisku preiskovanca in na osnovi strokovne presoje specialista. Podatki so se vpisovali v elektronski sistem za zbiranje podatkov. V elektronski vprašalnik so zdravniki v prvem delu vnesli demografske podatke, čas postavitve diagnoze astme, trenutno predpisana zdravila za astmo, meritve pljučne funkcije, ki je bila opravljena na dan obiska. Obstrukcijo smo definirali kot zmanjšanje indeksa Tiffeneau (T.I.) – razmerja med forsiranim izdihanim volumnom v prvi sekundi (FEV<sub>1</sub>) in vitalno kapaciteto (VC) – (FEV<sub>1</sub>/VC) za več kot 12 % pod normo (referenčno vrednost). Pri vseh bolnikih z obstrukcijo na dihalih je bil opravljen še bronhodilatacijski test. Test smo vrednotili kot pozitiven, če se je 15 minut po 4 vdihih (0,4 mg) salbutamola vrednost FEV<sub>1</sub> povečala za 12 % izhodne vrednosti in za vsaj 200 ml. V drugem delu so se vnesli možni razlogi za neurejeno astmo. Specialist je opravil neposredni kontrolni pregled uporabe vdihovalnika in ocenil, ali gre za dobro, sprejemljivo ali slabo uporabo vdihovalnika. Za dobro uporabo so zdravniki ocenili povsem pravilno uporabo vdihovalnika, za sprejemljivo uporabo, pri kateri so bolniki napravili eno ali več napak, ki pa niso bistveno zmanjšale prejeti odmerek zdravila, za slabo uporabo pa tisto, pri kateri so bolniki napravili kritično napako, zaradi katere niso dobili nič ali pa zelo malo zdravila. Sodelovanje (adherenco) smo ocenjevali na osnovi izdanih in porabljenih zdravil iz baze elektronskega recepta. Adherentni bolniki so bili tisti, katerim so bila zdravila za astmo redno predpisana, bolniki pa so zdravila v lekarni pravočasno prevzeli. Na osnovi strokovne presoje specialista smo ocenili bolnikovo razumevanje zdravil za astmo, neprimernost predpisanih zdravil ter morebitno prisotnost specifičnih sprožilcev astme v bolnikovem okolju. Iz medicinske dokumentacije in anamneze smo dobili podatke o pridruženih boleznih in stanjih ter izdanem načrtu samozdravljenja astme. V vprašalnik so zdravniki vpisali še število hudih poslabšanj v zadnjem letu in svojo strokovno presojo, ali gre pri bolniku za težko astmo. V raziskavi so bila huda poslabšanja opredeljena kot poslabšanja astme, pri katerih je bolnik potreboval pomoč zdravstvenega osebja v ambulanti ali na urgenci in je imel frekvenco dihanja več kot 30/min, srčni utrip več kot 120/min, nasičenost krvi s kisikom manj kot 90 % in PEF manj kot 50 % svoje najboljše vrednosti (<xref ref-type="bibr" rid="b1">1</xref>). Mednarodne smernice GINA opredeljujejo težko astmo kot astmo, ki potrebuje v zadnjih 12 mesecih zdravljenje z visokimi odmerki inhalacijskih glukokortikoidov (IGK) skupaj s še enim preprečevalnim zdravilom in/ali sistemskim glukokortikoidom (vsaj 6 mesecev) za doseganje urejenosti astme ali pa kadar astma kljub tej terapiji ostane neurejena. O visokem odmerku inhalacijskega glukokortikoida govorimo, ko dnevni odmerek zdravila preseže 800 µg pri budezonidu, 500 µg pri flutikazonu, 320 µg pri ciklezonidu, 800 µg pri mometazonu in 400 µg pri beklometazonu (HFA) (<xref ref-type="bibr" rid="b1">1</xref>).</p>
         </sec>
         <sec id="s2.3" sec-type="Statistične metode">
            <label>2.3</label>
            <title>Statistične metode</title>
            <p>Vse spremenljivke so bile povzete z opisno statistiko. Zvezne spremenljivke so bile prikazane s povprečjem in standardnim odklonom; porazdelitve so bile predstavljene tudi grafično. Kategorične spremenljivke so bile prikazane s številom in deleži (odstotki). Razen prikaza opisnih statistik ni bilo <italic toggle="yes">a priori</italic> predvidenih statističnih analiz. <italic toggle="yes">Post hoc</italic> je bila za eksplorativno analizo možne povezanosti izbranih spremenljivk s pojavljanjem hudih poslabšanj uporabljena logistična regresija. Izhodiščni model je vključeval naslednje spremenljivke: načrt samozdravljenja, razumevanje vloge zdravil, redno jemanje zdravil, pravilno tehniko inhalacije, ustrezno predpisano terapijo, pridružene bolezni in specifične sprožilce. Kot statistično značilni so bili obravnavani rezultati z vrednostjo p &lt; 0,05. Obdelava podatkov in analize so bile opravljene s programskim paketom R, verzija 3.3.1.</p>
            <p>Raziskavo je odobrila Komisija RS za medicinsko etiko 13. novembra 2017 (sklep št. 0120–560/2017). Raziskavo je finančno podprlo podjetje AstraZeneca, podružnica v Ljubljani.</p>
         </sec>
      </sec>
      <sec id="s3" sec-type="Rezultati">
         <label>3</label>
         <title>Rezultati</title>
         <p>Analiziran vzorec je zajel 323 bolnikov z astmo, ki so med 27. decembrom 2017 in 30. aprilom 2018 obiskali pnevmološke ambulante. V raziskavo je bilo vključenih 114 bolnikov (35,3 %) in 209 bolnic (64,7 %). Povprečna starost vseh bolnikov je bila 56,8 let. Bolniki so imeli astmo pred vključitvijo v raziskavo v povprečju 13,4 let. Kadilcev je bilo 48, nekadilcev ali bivših kadilcev pa 275 bolnikov (<table-wrap position="float" id="table2" orientation="portrait">
               <label>Tabela 2:</label>
               <caption>
                  <p> Glavne značilnosti bolnikov vključenih v raziskavo </p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Značilnost</th>
                        <th rowspan="1" colspan="1">Povprečje (SD)/n (%)</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Starost (leta)</p>
                           <p>≥ 65 let</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>56,8 (15,1)</p>
                           <p>112 (34,7 %)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Spol</p>
                           <p>Ženske</p>
                           <p>Moški</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>209 (64,7 %)</p>
                           <p>114 (35,3 %)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Telesna masa (kg)</td>
                        <td align="right" rowspan="1" colspan="1">80,3 (16,6)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>ITM (kg/m2)</p>
                           <p>≥ 30 kg/m2</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>28,8 (5,5)</p>
                           <p>123 (38,1)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Trajanje astme (leta)</td>
                        <td align="right" rowspan="1" colspan="1">13,5 (11,2)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Vsi bolniki (n = 323)</p>
                           <p>VC (l)</p>
                           <p>FEV<sub>1</sub>(l)</p>
                           <p>FEV<sub>1</sub>/VC (%)</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>3,2 (1,0)</p>
                           <p>2,3 (0,9)</p>
                           <p>72,5 (11,7 %)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Bolniki brez obstrukcije (n = 222)</p>
                           <p>VC (l)</p>
                           <p>FEV<sub>1</sub>(l)</p>
                           <p>FEV<sub>1</sub>/VC (%)</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>3,3 (1,0)</p>
                           <p>2,5 (0,86</p>
                           <p>76,5 (9,1 %)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Bolniki z obstrukcijo (n = 101)</p>
                           <p>VC (l)</p>
                           <p>FEV<sub>1</sub>(l)</p>
                           <p>FEV<sub>1</sub>/VC (%)</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>3,1 (1,0)</p>
                           <p>2,0 (0,8)</p>
                           <p>63,9 (12,1 %)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Kadilci</td>
                        <td align="right" rowspan="1" colspan="1">48 (14,9 %)</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <xref ref-type="table" rid="table2">Tabela 2</xref>). Normalno pljučno funkcijo je imelo 222 bolnikov (68,7 %), pri 101 bolniku (31,3 %) je bila spirografsko izmerjena obstrukcija na dihalih, zato so opravili spirometrijo še po bronhodilatatorju. Po bronhodilatatorju se je pljučna funkcija normalizirala pri 19 (5,8 %) bolnikih. Pri 82 (25,3 %) bolnikih je bila obstrukcija delno popravljiva (pozitiven bronhodilatacijski test) ali nepopravljiva (<xref ref-type="fig" rid="fig1">Slika 1</xref>). Od zdravil je olajševalec uporabljalo 300 bolnikov (92,9 %), brez olajševalca pa je bilo 23 bolnikov (7,1 %). Razen olajševalca ni uporabljalo druge terapije 19 bolnikov (5,9 %). Enotirno terapijo je uporabljalo 84 bolnikov (26,0 %), 2-tirno 152 (47,1 %), 3-tirno 49 (15,2 %), 4-tirno 17 (5,3 %) in 5-tirno 2 bolnika (0,6 %). Bioloških zdravil ni uporabljal nihče (<xref ref-type="table" rid="table3">Tabela 3</xref>).</p>
         <fig position="anchor" id="fig1" orientation="portrait">
            <label>Slika 1:</label>
            <caption>
               <p> Spirometrija in bronhodilatacijski test pri bolnikih z neurejeno astmo.</p>
            </caption>
            <p>
               <graphic xlink:href="2904-web-resources/image/zdravvestn-2904-sl-01.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <table-wrap position="anchor" id="table3" orientation="portrait">
            <label>Tabela 3:</label>
            <caption>
               <p> Trenutno razpoložljiva zdravila za astmo.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1"/>
                     <th rowspan="1" colspan="1">Samo olajševalec</th>
                     <th rowspan="1" colspan="1">1-tirno</th>
                     <th rowspan="1" colspan="1">2-tirno</th>
                     <th rowspan="1" colspan="1">3-tirno</th>
                     <th rowspan="1" colspan="1">4-tirno</th>
                     <th rowspan="1" colspan="1">5-tirno</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">19</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK</td>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">78</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">ALR</td>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">6</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">140</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK + ALR</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">12</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + ALR</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">31</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + LAMA</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">15</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + OGK</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">3</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + ALR + LAMA</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">11</td>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + ALR + OGK</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">3</td>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + ALR + drugo</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">2</td>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + LAMA + drugo</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">1</td>
                     <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">IGK/LABA + ALR + LAMA + drugo</td>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td rowspan="1" colspan="1"/>
                     <td align="right" rowspan="1" colspan="1">2</td>
                  </tr>
                  <tr>
                     <th rowspan="1" colspan="1"/>
                     <th rowspan="1" colspan="1">
                        <p>19</p>
                        <p>(5,9 %)</p>
                     </th>
                     <th rowspan="1" colspan="1">
                        <p>84</p>
                        <p>(26 %)</p>
                     </th>
                     <th rowspan="1" colspan="1">
                        <p>152</p>
                        <p>(47,1 %)</p>
                     </th>
                     <th rowspan="1" colspan="1">
                        <p>49</p>
                        <p>(15,2 %)</p>
                     </th>
                     <th rowspan="1" colspan="1">
                        <p>17</p>
                        <p>(5,3 %)</p>
                     </th>
                     <th rowspan="1" colspan="1">
                        <p>2</p>
                        <p>(0,6 %)</p>
                     </th>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>IGK: inhalacijski glukokortikoid, ALR: antilevkotrien, LABA: dolgodelujoči beta2 agonist, LAMA: dolgodelujoči antiholinergik, OGK: oralni glukokortikoid</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Načrt samozdravljenja astme je imelo 207 bolnikov (64,1 %), vlogo olajševalnih in preprečevalnih zdravil je razumelo 208 bolnikov (64,4 %), redno je zdravila jemalo 172 bolnikov (53,3 %), občasno 117 bolnikov (36,2 %), 34 bolnikov (10,4 %) pa zdravil sploh ni jemalo. Dobro tehniko uporabe vdihovalnika je pokazalo 160 bolnikov (49,5 %), sprejemljivo 109 bolnikov (33,7 %) in slabo 54 bolnikov (16,7 %). 240 bolnikov (74,3 %) je po mnenju specialista imelo predpisano ustrezno terapijo, 83 bolnikov (25,7 %) pa ne (<xref ref-type="table" rid="table4">Tabela 4</xref>).</p>
         <table-wrap position="anchor" id="table4" orientation="portrait">
            <label>Tabela 4:</label>
            <caption>
               <p> Načrt samozdravljenja, subjektivni dejavniki, ustreznost zdravljenja.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Ali ima bolnik načrt samozdravljenja?</td>
                     <td colspan="2" rowspan="1">
                        <p>Da</p>
                        <p>207</p>
                        <p>(64,1 %)</p>
                     </td>
                     <td colspan="2" rowspan="1">
                        <p>Ne</p>
                        <p>116</p>
                        <p>(35,9 %)</p>
                     </td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Ali menite, da bolnik razume vlogo olajševalnih in preprečevalnih zdravil za zdravljenje astme?</td>
                     <td colspan="2" rowspan="1">
                        <p>DA</p>
                        <p>208</p>
                        <p>(64,4 %)</p>
                     </td>
                     <td colspan="2" rowspan="1">
                        <p>NE</p>
                        <p>115</p>
                        <p>(35,6 %)</p>
                     </td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Ali menite, da bolnik redno jemlje zdravila (izdaja zdravil in dejanska poraba)?</td>
                     <td rowspan="1" colspan="1">
                        <p>Redno</p>
                        <p>172</p>
                        <p>(53,3 %)</p>
                     </td>
                     <td colspan="2" rowspan="1">
                        <p>Občasno</p>
                        <p>117</p>
                        <p>(36,2 %)</p>
                     </td>
                     <td rowspan="1" colspan="1">
                        <p>Ne jemlje</p>
                        <p>34</p>
                        <p>(10,5 %)</p>
                     </td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Ali zna bolnik pravilno pokazati tehniko inhaliranja svojega zdravila?</td>
                     <td rowspan="1" colspan="1">
                        <p>Da</p>
                        <p>160</p>
                        <p>(49,5 %)</p>
                     </td>
                     <td colspan="2" rowspan="1">
                        <p>Sprejemljivo</p>
                        <p>109</p>
                        <p>(33,7 %)</p>
                     </td>
                     <td rowspan="1" colspan="1">
                        <p>Slabo</p>
                        <p>54</p>
                        <p>(16,7 %)</p>
                     </td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Ali ima bolnik po vašem mnenju predpisano ustrezno terapijo za zdravljenje astme?</td>
                     <td colspan="2" rowspan="1">
                        <p>DA</p>
                        <p>240</p>
                        <p>(74,3 %)</p>
                     </td>
                     <td colspan="2" rowspan="1">
                        <p>NE</p>
                        <p>83</p>
                        <p>(25,7 %)</p>
                     </td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Pridružene bolezni, ki bi lahko pomembno vplivale na urejenost astme, je imelo 227 bolnikov (70,3 %), 96 bolnikov (29,7 %) pa takšnih bolezni ni imelo. Med pridruženimi boleznimi je prevladovala debelost pri 108 bolnikih (33,4 %), kronični rinosinusitis pri 93 bolnikih (28,8 %) in GERB pri 72 bolnikih (22,3 %) (<xref ref-type="table" rid="table5">Tabela 5</xref>). Dve ali več pridruženih bolezni je imelo 114 (36,8 %) bolnikov (<xref ref-type="fig" rid="fig2">Slika 2</xref>).</p>
         <table-wrap position="anchor" id="table5" orientation="portrait">
            <label>Tabela 5:</label>
            <caption>
               <p> Pridružene bolezni, ki bi lahko pomembno vplivale na urejenost astme.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Bolezen</th>
                     <th rowspan="1" colspan="1">Število bolnikov</th>
                     <th rowspan="1" colspan="1">%</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Debelost</td>
                     <td rowspan="1" colspan="1">108</td>
                     <td rowspan="1" colspan="1">33,4 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Rinosinusitis</td>
                     <td rowspan="1" colspan="1">93</td>
                     <td rowspan="1" colspan="1">28,8 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Gastroezofagealna refluksna bolezen (GERB)</td>
                     <td rowspan="1" colspan="1">72</td>
                     <td rowspan="1" colspan="1">22,3 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Depresija/anksioznost</td>
                     <td rowspan="1" colspan="1">31</td>
                     <td rowspan="1" colspan="1">9,6 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Obstruktivna apneja med spanjem</td>
                     <td rowspan="1" colspan="1">11</td>
                     <td rowspan="1" colspan="1">3,4 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Nutritivna alergija</td>
                     <td rowspan="1" colspan="1">7</td>
                     <td rowspan="1" colspan="1">2,2 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Drugo</td>
                     <td rowspan="1" colspan="1">59</td>
                     <td rowspan="1" colspan="1">18,3 %</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <fig position="anchor" id="fig2" orientation="portrait">
            <label>Slika 2:</label>
            <caption>
               <p> Porazdelitev števila pridruženih bolezni</p>
            </caption>
            <p>
               <graphic xlink:href="2904-web-resources/image/zdravvestn-2904-sl-02.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <p>Specifične sprožilce za neurejeno astmo je imelo 180 bolnikov (55,7 %), medtem ko 143 bolnikov (44,3 %) ni bilo izpostavljenih takšnim sprožilcem. Alergenom je bilo izpostavljenih 98 bolnikov (54,4 % vseh izpostavljenih), zdravilom 81 bolnikov (45,0 % vseh izpostavljenih) in kajenju v okolju 29 bolnikov (16,1 % vseh izpostavljenih). Od bolnikov, izpostavljenim specifičnim sprožilcem, jih je 152 (84,4 % vseh izpostavljenih) imelo prisoten 1 specifičen sprožilec in 28 (15,6 % vseh izpostavljenih) 2 specifična sprožilca (<xref ref-type="table" rid="table6">Tabela 6</xref>). Med zdravili, ki bi lahko vplivala na neurejeno astmo, so prevladovali zaviralci ACE (44,2 %) in blokatorji beta-receptorjev (24,7 %).</p>
         <table-wrap position="anchor" id="table6" orientation="portrait">
            <label>Tabela 6:</label>
            <caption>
               <p> Prisotnost specifičnih sprožilcev za neurejeno astmo.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Sprožilec</th>
                     <th rowspan="1" colspan="1">Število bolnikov</th>
                     <th rowspan="1" colspan="1">% (n = 180)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Alergeni</td>
                     <td rowspan="1" colspan="1">71</td>
                     <td rowspan="1" colspan="1">39,4 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Zdravila</td>
                     <td rowspan="1" colspan="1">63</td>
                     <td rowspan="1" colspan="1">35,0 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Kajenje</td>
                     <td rowspan="1" colspan="1">18</td>
                     <td rowspan="1" colspan="1">10,0 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Alergeni + zdravila</td>
                     <td rowspan="1" colspan="1">17</td>
                     <td rowspan="1" colspan="1">9,4 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Alergeni + kajenje</td>
                     <td rowspan="1" colspan="1">10</td>
                     <td rowspan="1" colspan="1">5,6 %</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Zdravila + kajenje</td>
                     <td rowspan="1" colspan="1">1</td>
                     <td rowspan="1" colspan="1">0,6 %</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Brez hudih poslabšanj astme v zadnjem letu je bilo 228 bolnikov (70,6 %), 95 bolnikov (29,4 %) pa je imelo v zadnjem letu eno ali več hudih poslabšanj (<xref ref-type="fig" rid="fig3">Slika 3</xref>). Logistična regresijska analiza je pokazala, da so bili obeti za hudo poslabšanje astme v zadnjem letu približno 2,6-krat večji v skupini bolnikov, ki ne razumejo vloge olajševalnih in preprečevalnih zdravil za zdravljenje astme (95 % IZ: [1,4; 4,8]; p = 0019), v primerjavi s tistimi, ki vlogo teh zdravil razumejo in približno 2,4-krat večji pri bolnikih, ki nimajo načrta samozdravljenja, kot pri tistih, ki načrt imajo (95 % IZ: [1,3; 4,3]; p = 0,042).</p>
         <fig position="anchor" id="fig3" orientation="portrait">
            <label>Slika 3:</label>
            <caption>
               <p> Število hudih poslabšanj astme v zadnjem letu.</p>
            </caption>
            <p>
               <graphic xlink:href="2904-web-resources/image/zdravvestn-2904-sl-03.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <p>Po oceni zdravnikov je imelo v raziskovalnem vzorcu bolnikov težko astmo po merilih GINA 74 bolnikov (22,9 %), medtem ko 249 bolnikov (77,1 %) ni imelo težke astme.</p>
      </sec>
      <sec id="s4" sec-type="Razpravljanje">
         <label>4</label>
         <title>Razpravljanje</title>
         <p>Astmo zdravimo stopenjsko v 5 korakih glede na trenutno urejenost bolezni (<xref ref-type="bibr" rid="b1">1</xref>). Urejenost astme opredeljujejo klinični simptomi, težo bolezni pa potrebna zdravila za doseganje urejenosti bolezni (<xref ref-type="bibr" rid="b7">7</xref>). Klinična raziskava GOAL (<italic toggle="yes">angl.</italic> The Gaining Optimal Asthma ControL study) je pokazale, da lahko s stopenjskim zdravljenjem in dobrim sodelovanjem (adherenco) bolnikov pri večini bolnikov dosežemo dober nadzor nad boleznijo (<xref ref-type="bibr" rid="b8">8</xref>), nasprotno pa opazovalne raziskave kažejo, da ima še vedno velik delež bolnikov z astmo neurejeno bolezen (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b3">3</xref>). Neurejena astma je povezana z večjim številom hudih poslabšanj, pospešenim upadom pljučne funkcije, zmanjšuje kakovost življenja, zmanjša bolnikovo storilnost in poveča stroške obravnave bolezni (<xref ref-type="bibr" rid="b9">9</xref>).</p>
         <p>V raziskavo smo vključili odrasle bolnike vseh starosti, ki so se vsaj leto dni že zdravili zaradi astme. 68,7 % vseh vključenih bolnikov z neurejeno astmo je imelo še normalno pljučno funkcijo, kar je dober napovednik za nadaljnji potek bolezni. Pri ostalih smo s spirometrijo odkrili obstruktivno ventilacijsko motnjo, ki je bila pri 5,8 % bolnikih povsem odpravljiva po inhalaciji bronhodilatatorja. Skupina bolnikov s tako obstrukcijo na dihalih nakazuje potrebo po preskoku v stopenjskem zdravljenju astme iz nižjega koraka v višji. Pri 24,3 % bolnikov je bila obstrukcija na dihalih delno odpravljiva (pozitiven bronhodilatacijski test) ali nepopravljiva. Del bolnikov iz te skupine predstavljajo bolniki s težko astmo in vnetnim preoblikovanjem dihalnih poti, ki povzroči trajno obstrukcijo. Drugi del so lahko bolniki, ki niso prejemali zadostnih odmerkov preprečevalnih zdravil, bodisi zaradi prenizkega predpisanega odmerka preprečevalnih zdravil ali nepravilne tehnike uporabe vdihovalnika ali slabega sodelovanja. Redno in pravilno jemanje inhalacijskih glukokortikoidov (IGK) v zadostni višini izboljša FEV<sub>1</sub> v nekaj dneh in doseže plato v približno 2 mesecih (<xref ref-type="bibr" rid="b10">10</xref>). Možno pa je, da se v tej skupini skriva tudi nekaj bolnikov z drugimi kroničnimi pljučnimi boleznimi, kot sta KOPB in kronični bronhiolitis.</p>
         <p>Kot glavna razloga za neurejeno astmo se v literaturi najpogosteje omenjata slabo sodelovanje bolnikov in napake pri uporabi vdihovalnikov (<xref ref-type="bibr" rid="b11">11</xref>). V naši raziskavi je redno jemalo zdravila 53,3 % bolnikov. Ocena sodelovanja na osnovi izdanih in porabljenih zdravil iz baze elektronskega recepta je zelo groba metoda, ki velikokrat preceni rednost jemanja zdravil. V kliničnih raziskavah se največkrat uporablja vračanje izdanih vdihovalnikov s pregledom porabljenih količin zdravila ali teže vdihovalnika, v zadnjem času pa so na voljo vdihovalniki z elektronskimi števci, ki beležijo čas aktivacije in učinkovitost manevra pri uporabi vdihovalnika. Spodbuden je nizek delež bolnikov (16,7 %), ki so slabo obvladali tehniko uporabe vdihovalnika. V zadnjih letih smo v Sloveniji ustvarili dobre pogoje za to, da se bolnik nauči pravilne tehnike uporabe vdihovalnikov tako v specialistični ambulantah kot v referenčnih ambulantah na primarni ravni. Tehnika uporabe vdihovalnika se mora stalno preverjati ob kontrolnih pregledih (<xref ref-type="bibr" rid="b12">12</xref>). Najpogostejši dejavnik, ki je lahko povezan z neurejeno astmo, so v naši raziskavi bile pridružene bolezni, zlasti debelost, rinosinusitis in GERB. Zmanjševanje telesne teže izboljša urejenost astme, pljučno funkcijo, kakovost življenja in porabo zdravil (<xref ref-type="bibr" rid="b13">13</xref>). Povezava med zgornjimi in spodnjimi dihali pri astmi je že dolgo poznana. Zdravljenje pridruženega tako alergijskega rinitisa kot kroničnega rinosinusitisa, predvsem če je ta povezan z nosno polipozo, izboljša nadzor nad astmo (<xref ref-type="bibr" rid="b14">14</xref>). Večina epidemioloških raziskav kaže, da ima vsaj 80 % bolnikov z astmo tudi bolezen nosu (<xref ref-type="bibr" rid="b1">1</xref>). Na osnovi strokovne presoje specialistov smo v naši raziskavi le pri 28,8 % bolnikih odkrili kronični rinosinusitis kot pomemben potencialni dejavnik tveganja za neurejeno astmo. V to skupino so bili vključeni zlasti bolniki s pogosto ali stalno nosno simptomatiko, pri katerih medikamentno in/ali kirurško zdravljenje ni bilo dovolj uspešno. Zdravljenje z inhibitorji protonske črpalke pri bolnikih z astmo in GERB je uspešno zlasti pri bolnikih, ki imajo jasne simptome GERB-a in nočne respiracijske simptome (<xref ref-type="bibr" rid="b15">15</xref>). Pri več kot polovici bolnikov so bili prisotni specifični sprožilci kot dejavnik, ki je lahko povezan z neurejeno astmo. V tej skupini prevladujejo zdravila (največ zaviralci ACE), izpostavljenost alergenom, v manjši meri pa kajenje. Čeprav slovenske in mednarodne smernice GINA omenjajo med zdravili, ki lahko predstavljajo tveganje za neurejeno astmo tudi zaviralce ACE, neposrednih dokazov za to v literaturi ni. Pri manjšem deležu bolnikov z astmo lahko zaviralci ACE povzročijo kašelj, zato jih moramo ukiniti. V raziskavo so bili vključeni odrasli bolniki vseh starosti. S staranjem se število komorbidnosti pri bolnikih z astmo povečuje in s tem tudi potreba po njihovem zdravljenju. Preverba zdravil, ki jih bolnik z astmo stalno jemlje zaradi komorbidnosti in zamenjava le-teh z bolj varnimi, če je seveda to mogoče, je nujen ukrep za dober nadzor astme. Alergenom v domačem okolju ali na delovnem mestu se lahko popolnoma ali delno izognemo. Bolnika z blago ali zmerno alergijsko astmo pa lahko zdravimo s specifično imunoterapijo. Kajenje zmanjša učinkovitost zdravljenja z inhalacijskimi glukokortikoidi, zato je te bolnike potrebno aktivno spodbujati k opustitvi kajenja (<xref ref-type="bibr" rid="b1">1</xref>).</p>
         <p>Neurejena astma že sama po sebi poveča tveganje za poslabšanja (<xref ref-type="bibr" rid="b16">16</xref>). Drugi pomembni, od urejenosti astme neodvisni dejavniki tveganja za poslabšanje astme, so še: vsaj eno ali več poslabšanj v predhodnem letu, slaba adherenca, nepravilna uporaba vdihovalnika, kronični rinosinusitis in kajenje (<xref ref-type="bibr" rid="b17">17</xref>). V našem vzorcu bolnikov z neurejeno astmo je imelo eno ali več hudih poslabšanj manj kot 30 % bolnikov. Regresijska analiza je pokazala, da sta najpomembnejša dejavnika povezana s hudimi poslabšanji v zadnjem letu: nerazumevanje vloge preprečevalnih in olajševalnih zdravil in da zdravnik ne izda načrta za samozdravljenja astme. Razumevanje vloge zdravil pri astmi je eden ključnih elementov za doseganje nadzora nad boleznijo. Vključeno mora biti v zdravstveno vzgojo zdravnika kot medicinske sestre, ki je je deležen bolnik (<xref ref-type="bibr" rid="b1">1</xref>). Učenje samozdravljenja astma vključuje tri komponente: bolnikovo oceno simptomov in maksimalnega pretoka v izdihu, pisna navodila za redno zdravljenje, prepoznavanje ter ukrepanje ob poslabšanju astme in redne kontrole urejenosti bolezni, zdravljenja in ocene pravilne uporabe vdihovalnikov (<xref ref-type="bibr" rid="b18">18</xref>). Učenja samozdravljenja astme morajo biti deležni vsi bolniki z astmo.</p>
         <p>Neurejena astma ni sinonim za težko astmo. Z odpravo dejavnikov, ki so lahko vzrok za neurejeno astmo, lahko astmo pri večini bolnikov uredimo. Vzrok za težko astmo ni v naštetih dejavnikih za neurejeno astmo, ampak v naravi bolezni. Podatkov o prevalenci težke astme po svetu je malo. Izvedenci ocenjujejo, da ima težko astmo 5–10 % bolnikov z astmo (<xref ref-type="bibr" rid="b4">4</xref>). Nizozemska opazovalna raziskava je ta delež še zmanjšala na 4,5 %. V naši raziskavi je ocenjen delež težke astme v vzorcu odraslih bolnikov z neurejeno astmo 22,9 %. Če upoštevamo 38-odstotno prevalenco neurejene astme v Sloveniji, ugotovljeno s predhodno raziskavo, je delež težke astme v Sloveniji vsaj 8 %.</p>
         <p>Čeprav je bila raziskava narejena na izbrani populacije bolnikov z neurejeno astmo v zunajbolnišničnih pnevmoloških ambulantah, menimo, da je vzorec reprezentativen, ker so bile izbrane ambulante enakomerno razpršene po celi Sloveniji. V raziskavo pa so bili vključeni tako bolniki, ki so se že nekaj časa obravnavali v specialističnih ambulantah, kot bolniki, ki so bili zaradi neurejene astme napoteni s primarne ravni. Družinski zdravniki bolnike z neurejeno astmo najpogosteje napotijo k specialistu. Seveda pa potencialni manjši delež bolnikov z neurejeno astmo, vodeno na primarni ravni, ni bil zajet. Raziskava je bila izvedena v zimskem in pomladanskem času, ko je pojavnost okužb dihal večja. Bolnikov, ki so imeli poslabšanje astme ali okužbo dihal v zadnjem mesecu, nismo vključili v raziskavo. Velika prednost raziskave je celovita ocena dejavnikov tveganja za neurejenost astme. Poleg ocene adherence in tehnike uporabe vdihovalnika, ki se v raziskavah največkrat uporabljata, smo dodali še pridružene bolezni in specifične sprožilce.</p>
         <p>Med slabost raziskave vsekakor štejemo možnost neustrezne subjektivne strokovne presoje specialista zlasti pri oceni pravilne tehnike uporabe vdihovalnika, oceni specifičnih sprožilcev za neurejeno astmo in oceni ustreznosti dosedanje terapije za zdravljenje astme.</p>
      </sec>
      <sec id="s5" sec-type="Zaključek">
         <label>5</label>
         <title>Zaključek</title>
         <p>Z raziskavo smo potrdili, da so najpogostejši dejavniki, ki so povezani z neurejeno astmo pri vzorcu odraslih bolnikov v zunajbolnišničnih pnevmoloških ambulantah po Sloveniji, pridružene bolezni, specifični sprožilci in slabo sodelovanje bolnikov. Tretjina bolnikov z neurejeno astmo ima kljub zdravljenju še vedno vsaj eno hudo poslabšanje bolezni v zadnjem letu. Nerazumevanje vloge zdravil in odsotnost individualiziranega načrta samozdravljenja sta najpomembnejša vzroka za huda poslabšanja. V prihodnosti bo potrebno bolnike z astmo še bolje usposobiti in jih vse oskrbeti z individualiziranim načrtom samozdravljenja astme.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <mixed-citation publication-type="webpage">
                    <article-title>Global Strategy for Asthma Management and Prevention</article-title>.
                    <year>2018</year>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2018-08-25">cited 2018 Aug 25</date-in-citation>]. 
                    <comment>Available from:<uri>https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdfi</uri>
               </comment>. 
                </mixed-citation>
         </ref>
         <ref id="b2">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Price</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fletcher</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>van der Molen</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey</article-title>. 
                    <source>NPJ Prim Care Respir Med</source>. 
                    <year>2014</year>
                    <month>Jun</month>;
                    <volume>24</volume>(
                    <issue>1</issue>):
                    <fpage>14009</fpage>. 
                    <pub-id pub-id-type="doi">10.1038/npjpcrm.2014.9</pub-id>
                    <pub-id pub-id-type="pmid">24921985</pub-id>
                    <issn>2055-1010</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Janežič</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Locatelli</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kos</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>44th ESCP International Symposium on Clinical Pharmacy Medicines Information: Making Better Decisions : Lisbon, Portugal, 28-30 October 2015</article-title>. 
                    <source>Int J Clin Pharm</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>38</volume>(
                    <issue>2</issue>):
                    <fpage>470</fpage>–
                    <lpage>598</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s11096-015-0240-y</pub-id>
                    <pub-id pub-id-type="pmid">26739129</pub-id>
                    <issn>2210-7703</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Chung</surname>
                     <given-names>KF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wenzel</surname>
                     <given-names>SE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Brozek</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bush</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Castro</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sterk</surname>
                     <given-names>PJ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma</article-title>. 
                    <source>Eur Respir J</source>. 
                    <year>2014</year>
                    <month>Feb</month>;
                    <volume>43</volume>(
                    <issue>2</issue>):
                    <fpage>343</fpage>–
                    <lpage>73</lpage>. 
                    <pub-id pub-id-type="doi">10.1183/09031936.00202013</pub-id>
                    <pub-id pub-id-type="pmid">24337046</pub-id>
                    <issn>0903-1936</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Škrgat</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Triller</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Košnik</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Poplas Susič</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Petek</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vodopivec Jamšek</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Priporočila za obravnavo bolnika z astmo na primarni in specialistični pulmološki ravni v Sloveniji</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2016</year>;
                    <volume>85</volume>(
                    <issue>11/12</issue>):
                    <fpage>693</fpage>–
                    <lpage>706</lpage>.
                    <pub-id pub-id-type="doi">10.6016/ZdravVestn.2470</pub-id>
                    <issn>0350-0063</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Terl</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sedlák</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cap</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dvořáková</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kašák</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kočí</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy</article-title>. 
                    <source>Allergy</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>72</volume>(
                    <issue>9</issue>):
                    <fpage>1279</fpage>–
                    <lpage>87</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/all.13165</pub-id>
                    <pub-id pub-id-type="pmid">28328094</pub-id>
                    <issn>0105-4538</issn>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Taylor</surname>
                     <given-names>DR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bateman</surname>
                     <given-names>ED</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boulet</surname>
                     <given-names>LP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boushey</surname>
                     <given-names>HA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Busse</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Casale</surname>
                     <given-names>TB</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A new perspective on concepts of asthma severity and control</article-title>. 
                    <source>Eur Respir J</source>. 
                    <year>2008</year>
                    <month>Sep</month>;
                    <volume>32</volume>(
                    <issue>3</issue>):
                    <fpage>545</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1183/09031936.00155307</pub-id>
                    <pub-id pub-id-type="pmid">18757695</pub-id>
                    <issn>0903-1936</issn>
                </mixed-citation>
         </ref>
         <ref id="b8">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bateman</surname>
                     <given-names>ED</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boushey</surname>
                     <given-names>HA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bousquet</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Busse</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Clark</surname>
                     <given-names>TJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pauwels</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>GOAL Investigators Group</collab>
                    </person-group>. 
                    <article-title>Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study</article-title>. 
                    <source>Am J Respir Crit Care Med</source>. 
                    <year>2004</year>
                    <month>Oct</month>;
                    <volume>170</volume>(
                    <issue>8</issue>):
                    <fpage>836</fpage>–
                    <lpage>44</lpage>. 
                    <pub-id pub-id-type="doi">10.1164/rccm.200401-033OC</pub-id>
                    <pub-id pub-id-type="pmid">15256389</pub-id>
                    <issn>1073-449X</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Demoly</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Annunziata</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gubba</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adamek</surname>
                     <given-names>L</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years</article-title>. 
                    <source>Eur Respir Rev</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>21</volume>(
                    <issue>123</issue>):
                    <fpage>66</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1183/09059180.00008111</pub-id>
                    <pub-id pub-id-type="pmid">22379176</pub-id>
                    <issn>0905-9180</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Reddel</surname>
                     <given-names>HK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jenkins</surname>
                     <given-names>CR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Marks</surname>
                     <given-names>GB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ware</surname>
                     <given-names>SI</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Xuan</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salome</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Optimal asthma control, starting with high doses of inhaled budesonide</article-title>. 
                    <source>Eur Respir J</source>. 
                    <year>2000</year>
                    <month>Aug</month>;
                    <volume>16</volume>(
                    <issue>2</issue>):
                    <fpage>226</fpage>–
                    <lpage>35</lpage>. 
                    <pub-id pub-id-type="doi">10.1034/j.1399-3003.2000.16b08.x</pub-id>
                    <pub-id pub-id-type="pmid">10968496</pub-id>
                    <issn>0903-1936</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Haughney</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Price</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kaplan</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chrystyn</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Horne</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>May</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Achieving asthma control in practice: understanding the reasons for poor control</article-title>. 
                    <source>Respir Med</source>. 
                    <year>2008</year>
                    <month>Dec</month>;
                    <volume>102</volume>(
                    <issue>12</issue>):
                    <fpage>1681</fpage>–
                    <lpage>93</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.rmed.2008.08.003</pub-id>
                    <pub-id pub-id-type="pmid">18815019</pub-id>
                    <issn>0954-6111</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Košnik</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Triller</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Šelb</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Mnenje pulmologov o pomenu vdihovalnikov pri bolnikih z astmo ali KOPB</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2017</year>;
                    <volume>86</volume>(
                    <issue>3-4</issue>):
                    <fpage>105</fpage>–
                    <lpage>14</lpage>.
                    <pub-id pub-id-type="doi">10.6016/ZdravVestn.2472</pub-id>
                    <issn>0350-0063</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Adeniyl</surname>
                     <given-names>FB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Young</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Weight loss intervention for chronic asthma</article-title>. 
                    <source>Cochrane Database Syst Rev</source>. 
                    <year>2012</year>;
                    <volume>7</volume>:
                    <fpage>CD009339</fpage>.
                    <issn>1469-493X</issn>
                    <pub-id pub-id-type="doi">10.1002/14651858.CD009339.pub2</pub-id>
                    <pub-id pub-id-type="pmid">22786526</pub-id>
                    <issn>1469-493X</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bousquet</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schünemann</surname>
                     <given-names>HJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Samolinski</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Demoly</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baena-Cagnani</surname>
                     <given-names>CE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bachert</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>World Health Organization Collaborating Center for Asthma and Rhinitis</collab>
                    </person-group>. 
                    <article-title>Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs</article-title>. 
                    <source>J Allergy Clin Immunol</source>. 
                    <year>2012</year>
                    <month>Nov</month>;
                    <volume>130</volume>(
                    <issue>5</issue>):
                    <fpage>1049</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jaci.2012.07.053</pub-id>
                    <pub-id pub-id-type="pmid">23040884</pub-id>
                    <issn>0091-6749</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sopo</surname>
                     <given-names>SM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Radzik</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Calvani</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Does treatment with proton pump inhibitors for GERD improve asthma symptoms in children with asthma and GERD? A systematic revie</article-title>. 
                    <source>J Investig Allergol Clin Immunol</source>. 
                    <year>2009</year>;
                    <volume>19</volume>(
                    <issue>1</issue>):
                    <fpage>1</fpage>–
                    <lpage>5</lpage>.
                    <pub-id pub-id-type="pmid">19274922</pub-id>
                    <issn>1018-9068</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Meltzer</surname>
                     <given-names>EO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Busse</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wenzel</surname>
                     <given-names>SE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Belozeroff</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weng</surname>
                     <given-names>HH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Feng</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation</article-title>. 
                    <source>J Allergy Clin Immunol</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>127</volume>(
                    <issue>1</issue>):
                    <fpage>167</fpage>–
                    <lpage>72</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jaci.2010.08.042</pub-id>
                    <pub-id pub-id-type="pmid">21093024</pub-id>
                    <issn>0091-6749</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Loymans</surname>
                     <given-names>RJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Honkoop</surname>
                     <given-names>PJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Termeer</surname>
                     <given-names>EH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Snoeck-Stroband</surname>
                     <given-names>JB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Assendelft</surname>
                     <given-names>WJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schermer</surname>
                     <given-names>TR</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model</article-title>. 
                    <source>Thorax</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>71</volume>(
                    <issue>9</issue>):
                    <fpage>838</fpage>–
                    <lpage>46</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-208138</pub-id>
                    <pub-id pub-id-type="pmid">27044486</pub-id>
                    <issn>0040-6376</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gibson</surname>
                     <given-names>PG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Powell</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Coughlan</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wilson</surname>
                     <given-names>AJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Abramson</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haywood</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Self-management education and regular practitioner review for adults with asthma</article-title>. 
                    <source>Cochrane Database Syst Rev</source>. 
                    <year>2003</year>;(
                    <issue>1</issue>):
                    <fpage>CD001117</fpage>.
                    <pub-id pub-id-type="pmid">12535399</pub-id>
                    <issn>1469-493X</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-sl" xml:lang="sl" article-type="other">
      <front-stub>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject/>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl"/>
            <alt-title alt-title-type="running-head" xml:lang="sl">Opazovalna raziskava odraslih bolnikov z neurejeno astmo</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Kajba</surname>
                  <given-names>Stanislav</given-names>
               </name>
               <xref ref-type="aff" rid="sl-aff1">1</xref>
               <xref ref-type="corresp" rid="sl-corr"/>
            </contrib>
         </contrib-group>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Almost 50 % of patients in clinical practice still have poor control of their asthma despite treatment according to the GINA (Global Initiative for Asthma) criteria. The most common causes of uncontrolled asthma are: poor inhaler technique, poor medication adherence, incorrect diagnosis, comorbidities (rhinosinusitis, GERD (Gastroesophageal Reflux Disease), obesity, depression, obstructive sleep apnea) and ongoing exposure to specific triggers (allergens, drugs and smoking).</p>
            <p>Methods: Observational study was conducted on 323 adult patients with uncontrolled asthma in 14 outpatient pulmonology practices in Slovenia in the period from December 2017 to April 2018. Data about common causes of uncontrolled asthma and exacerbations in the last year were entered in electronic case report forms at the investigator’s site.</p>
            <p>Results: The most common factors associated with uncontrolled asthma were comorbidities in 70 % (obesity 33 %, rhinosinusitis 28 %, GERD 22 %), specific triggers in 56 % (ongoing exposure to allergens 39 %, drugs 35 %, smoking 10 %) and poor medication adherence in 53 %. Thirty percent of patients had one or more severe exacerbations in the last year. Patient’s non-understanding of the role of asthma medications (95 % IZ: [1.4; 4.8]; p = 0.019) and the lack of self-management plan (95 % IZ: [1.3; 4.3]; p = 0.042) were the most important factors in the logistic regression model for severe exacerbations. 23 % of included patients had severe asthma according to the GINA criteria.</p>
            <p>Conclusion: Obesity, specific triggers and poor medication adherence are the most important factors for uncontrolled asthma in the adult patient sample with uncontrolled asthma in pneumology outpatient clinics in Slovenia. Severe exacerbations are still present in these patients. Therefore, better education and providing all asthma patients with written self-management plan would be warranted in the future.</p>
         </abstract>
      </front-stub>
      <body>
         <sec id="sl-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>Asthma is a common chronic disease of the respiratory tract. The objective of treating asthma according to the Global Initiative for Asthma (GINA) guidelines is to achieve asthma control (<xref ref-type="bibr" rid="sl-b2">2</xref>). Asthma control includes controlling the symptoms and lowering the risk for: acute asthmatic exacerbation, development of a permanent obstruction in the respiratory tract, and the onset of local and systemic effects of medications. The assessment of symptom control is based on the checking four clinical parameters during the last four weeks before a patient’s assessment. With regard to the presence of daily and nightly symptoms, the use of the controller and the patient’s limited activity, asthma can be defined as either controlled, partially controlled or uncontrolled (<xref ref-type="table" rid="sl-table1">Table 1</xref>).</p>
            <table-wrap position="anchor" id="sl-table1" orientation="portrait">
               <label>Table 1:</label>
               <caption>
                  <p> Assessment of the level of asthma control (GINA 2018)</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Parameters of asthma control </th>
                        <th align="center" colspan="3" rowspan="1">Level of asthma control </th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Last 4 weeks before the exam</th>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Controlled</th>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Partially controlled</th>
                        <th content-type="table-subhead" rowspan="1" colspan="1">Uncontrolled</th>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Daily asthma symptoms</p>
                           <p>(symptoms occurring more than 2 times per week)</p>
                        </td>
                        <td rowspan="1" colspan="1">No</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Nocturnal asthma symptoms</p>
                           <p>(any time in the past 4 weeks)</p>
                        </td>
                        <td rowspan="1" colspan="1">No</td>
                        <td rowspan="1" colspan="1">1 – 2 parameters</td>
                        <td rowspan="1" colspan="1">3 – 4 parameters</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Using a short-term controller</p>
                           <p>(more than 2 times per week)</p>
                        </td>
                        <td rowspan="1" colspan="1">No</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Limited activities because of asthma</p>
                           <p>(any time in the past 4 weeks)</p>
                        </td>
                        <td rowspan="1" colspan="1">No</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>The international study REALISE (The REcognise Asthma and LInk to Symptoms and Experience), which included 8000 asthma patients aged between 18 to 50, showed that in spite of therapy, 45% of patients have uncontrolled asthma. The data on patients was obtained through email surveys in 11 European countries. The level of asthma control was assessed according to GINA criteria (<xref ref-type="bibr" rid="sl-b2">2</xref>). The study conducted in Slovenia showed that with 38% of asthma patients the disease is uncontrolled (<xref ref-type="bibr" rid="sl-b3">3</xref>).</p>
            <p>The most frequent causes for uncontrolled asthma are: irregular medication adherence, poor patient cooperation, incorrect asthma diagnosis, comorbidities that cause complications, such as rhinosinusitis, GERD (Gastroesophageal Reflux Disease), anxiety and depression, obesity, obstructive sleep apnoea, smoking, and ongoing exposure to specific triggers (beta blockers, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs or exposure to allergens in the work or home environment) (<xref ref-type="bibr" rid="sl-b1">1</xref>). Treatment-resistant severe asthma resulting from uncontrolled asthma occurs in a small share of patients. The Dutch monitoring study discovered that severe asthma – according to the measures of the European Respiratory Society and the American Thoracic Society (ERS/ATS)(<xref ref-type="bibr" rid="sl-b4">4</xref>) – is only present in 4.5% of asthma patients (<xref ref-type="bibr" rid="sl-b5">5</xref>). In the past few years we developed new biological drugs that decrease the number of moderate and severe exacerbations for some of the patients with severe asthma, and lower the need for treatment with systemic glucocorticoids.  The phenotypic definition of asthma plays a key role in the selection of a biological drug. Anti-IgE monoclonal antibodies (omalizumab) are used for treating severe allergy asthma, while anti-IL-5 monoclonal antibodies (mepolizumab, reslizumab) and IL-5R (benralizumab) are used for treating non-allergic eosinophilic asthma. At the moment no other effective biological drugs for other phenotypes of severe asthma are yet in clinical use (<xref ref-type="bibr" rid="sl-b6">6</xref>).</p>
            <p>In the article we present the results of the study of adult patients with uncontrolled asthma, who were treated in a 5-month period in 2017 and 2018 in outpatient specialist clinics in Slovenia.</p>
            <p>The goal of our study was to find the most frequent causes for uncontrolled asthma on a sample of adult asthma patients in Slovenia. The article also focuses on the frequency of severe asthma exacerbations in the past year, the connection between the causes for uncontrolled asthma and an increasing number of severe exacerbation and the estimation of the share of patients with severe asthma.</p>
         </sec>
         <sec id="sl-s2" sec-type="The material and the methods">
            <label>2</label>
            <title>The material and the methods</title>
            <sec id="sl-s2.1" sec-type="Subjects">
               <label>2.1</label>
               <title>Subjects</title>
               <p>In this non-interventional observational cross-section study pulmonology and internal medicine specialists included adult patients with uncontrolled asthma, who were treated between December 2017 and April 2018 in one of 14 outpatient specialist clinics in Slovenia. The treated patients came in for their regular check-up at the specialist clinic, or were referred there by their family doctors because of uncontrolled asthma. Only patients over 18 years of age with a clinical asthma diagnosis confirmed more than 12 months prior to the study through a positive bronchodilator test or a positive methacholine challenge test (PD20 with 2 mg methacholine or less) were accepted for participation. Asthma had to be uncontrolled according to GINA criteria (<xref ref-type="table" rid="sl-table1">Table 1</xref>). If the patients had an exacerbation of their asthma that required a change of the sustained treatment one month before the start of the study, they were not included for participation. Other exclusionary measures included acute disease, pregnancy and participation in any clinical trials in the past 12 months.</p>
               <fig position="anchor" id="sl-fig1" orientation="portrait">
                  <label>Figure 1:</label>
                  <caption>
                     <p> Spirometry and the bronchodilator test for patients with uncontrolled asthma.</p>
                  </caption>
                  <p>
                     <graphic xlink:href="2904-en-web-resources/image/zdravvestn-2904-en-01.png"
                              position="float"
                              orientation="portrait"/>
                  </p>
               </fig>
            </sec>
            <sec id="sl-s2.2" sec-type="The method">
               <label>2.2</label>
               <title>The method</title>
               <p>The data was collected from the patients’ medical records, based on the information the physician obtained from the subjects during the check-up, and based on the specialist’s professional assessment. The data was entered in an electronic system for data collection. In the first part of the electronic questionnaire the physicians entered the demographic data, when the asthma diagnosis was first made, the currently prescribed asthma medication, and pulmonary function tests conducted on the date of visit. The obstruction was defined as a decrease of the Tiffeneau index (T.I.) – the ratio between the forced exhaled volume in the first second (FEV<sub>1</sub>) and the vital capacity (VC) – (FEV<sub>1</sub>/VC) by more than 12% below the reference value. All patients with a respiratory obstruction were also given a bronchodilator test. The test was deemed positive, if, after 15 minutes and 4 inhalations of (0.4 mg) salbumatol, the FEV<sub>1</sub> value increased by 12% of the exit value, and by at least 200 ml. In the second part the possible reasons for uncontrolled asthma were entered. The specialist conducted a direct control check of the use of the inhaler and assessed whether it was proper, acceptable or poor. Physicians rated inhaler use as proper when the patient used it completely correctly, as acceptable when they made one or several mistakes that did not significantly impact the administered dosage of the medication, and as poor when the patient made a critical error that resulted in them receiving no or just a small dose of medication. Adherence was estimated based on the difference between medications issued and medications used, as taken from the electronic prescription database. Adherent patients were those whose asthma medications were regularly prescribed, and they picked them up at the pharmacy on time. Based on a specialist’s professional judgment we assessed the patient’s understanding of asthma medication, the unsuitability of prescribed medication and any potential presence of specific asthma triggers in the patient’s environment. We obtained the data on comorbidities and conditions, and the asthma self-management plan they were issued from their medical documentation and anamnesis. The physicians also entered the number of severe exacerbations in the past year and their professional judgement about whether the patient is suffering from severe asthma. Severe exacerbations were defined in the study as asthma exacerbation in which the patient required help from the medical staff at a clinic or the emergency room, and had a breathing frequency above 30/min, a heart rate above 120 bpm, oxygen saturation below 90%, and a PEF rate below 50% of the top value (<xref ref-type="bibr" rid="sl-b1">1</xref>). GINA international guidelines define severe asthma as asthma that has in the past 12 months required treatment with high dosages of inhaled glucocorticoids (IGK) along with one more blocking drug and/or system glucocorticoid (for at least 6 months) for achieving asthma control, or, when asthma remains uncontrolled, even after such therapy. A high dosage of inhaled glucocorticoid is when the daily dosage of the medication surpasses 800 µg for Budesonide, 500 µg for Fluticasone, 320 µg for Ciclesonide, 800 µg for Mometasone and 400 µg for Beclomethasone (HFA) (<xref ref-type="bibr" rid="sl-b1">1</xref>).</p>
               <table-wrap position="anchor" id="sl-table2" orientation="portrait">
                  <label>Table 2:</label>
                  <caption>
                     <p> Main characteristic of participating patients </p>
                  </caption>
                  <table>
                     <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th rowspan="1" colspan="1">Characteristic</th>
                           <th rowspan="1" colspan="1">Average (SD)/n (%)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="1" colspan="1">
                              <p>Age (years)</p>
                              <p>≥ 65 years</p>
                           </td>
                           <td rowspan="1" colspan="1">
                              <p>56.8 (15.1)</p>
                              <p>112 (34.7%)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">
                              <p>Sex</p>
                              <p>Women</p>
                              <p>Men</p>
                           </td>
                           <td rowspan="1" colspan="1">
                              <p>209 (64.7%)</p>
                              <p>114 (35.3%)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Body mass (kg)</td>
                           <td align="right" rowspan="1" colspan="1">80.3 (16.6)</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">
                              <p>BMI (kg/m2)</p>
                              <p>≥ 30 kg/m2</p>
                           </td>
                           <td rowspan="1" colspan="1">
                              <p>28.8 (5.5)</p>
                              <p>123 (38.1%)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Duration of asthma (years)</td>
                           <td align="right" rowspan="1" colspan="1">13.5 (11.2)</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">
                              <p>All patients (n = 323)</p>
                              <p>VC (l)</p>
                              <p>FEV<sub>1</sub>(l)</p>
                              <p>FEV<sub>1</sub>/VC (%)</p>
                           </td>
                           <td rowspan="1" colspan="1">
                              <p>3.2 (1.0)</p>
                              <p>2.3 (0.9)</p>
                              <p>72.5 (11.7%)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">
                              <p>Patients without an obstruction (n=222)</p>
                              <p>VC (l)</p>
                              <p>FEV<sub>1</sub>(l)</p>
                              <p>FEV<sub>1</sub>/VC (%)</p>
                           </td>
                           <td rowspan="1" colspan="1">
                              <p>3.3 (1.0)</p>
                              <p>2.5 (0.86)</p>
                              <p>76.5 (9.1%)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">
                              <p>Patients with an obstruction (n=101)</p>
                              <p>VC (l)</p>
                              <p>FEV<sub>1</sub>(l)</p>
                              <p>FEV<sub>1</sub>/VC (%)</p>
                           </td>
                           <td rowspan="1" colspan="1">
                              <p>3.1 (1.0)</p>
                              <p>2.0 (0.8)</p>
                              <p>63.9 (12.1%)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Smokers</td>
                           <td align="right" rowspan="1" colspan="1">48 (14.9%)</td>
                        </tr>
                     </tbody>
                  </table>
               </table-wrap>
            </sec>
            <sec id="sl-s2.3" sec-type="Statistical methods">
               <label>2.3</label>
               <title>Statistical methods</title>
               <p>All variables were summed up using descriptive statistics. Continuous variables were displayed using a median and standard deviation; dispersions were also presented graphically. Categorical variables were displayed with the number and the shares (percentages). Except for the presentation of descriptive statistics there were no <italic toggle="yes">a priori</italic> statistical analyses planned. Logistic regression was used <italic toggle="yes">post hoc</italic> for exploratory analysis of possible correlation of select variables with the onset of severe exacerbation. The base model included the following variables: self-management plans, understanding the role of medication, regular medication application, correct inhalation technique, correctly prescribed therapy, comorbidities, and specific triggers. The results with the value of p &lt; 0.05 were marked as statistically significant. Data processing and analyses were performed using the R software environment, version 3.3.1.</p>
               <p>The study was approved by the National Medical Ethics Committee of the Republic of Slovenia in November 2017 (decision no.: 0120–560/2017). The study was financially supported by AstraZeneca’s Ljubljana subsidiary.</p>
               <table-wrap position="anchor" id="sl-table3" orientation="portrait">
                  <label>Table 3:</label>
                  <caption>
                     <p> The currently available asthma medications.</p>
                  </caption>
                  <table>
                     <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th rowspan="1" colspan="1"/>
                           <th rowspan="1" colspan="1">Controller only</th>
                           <th rowspan="1" colspan="1">1-tier</th>
                           <th rowspan="1" colspan="1">2-tier</th>
                           <th rowspan="1" colspan="1">3-tier</th>
                           <th rowspan="1" colspan="1">4-tier</th>
                           <th rowspan="1" colspan="1">5-tier</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">19</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK</td>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">78</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">ALR</td>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">6</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">140</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK + ALR</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">12</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + ALR</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">31</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + LAMA</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">15</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + OGK</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">3</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + ALR + LAMA</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">11</td>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + ALR + OGK</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">3</td>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + ALR + drugo</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">2</td>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + LAMA + drugo</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">1</td>
                           <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">IGK/LABA + ALR + LAMA + other</td>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td rowspan="1" colspan="1"/>
                           <td align="right" rowspan="1" colspan="1">2</td>
                        </tr>
                        <tr>
                           <th rowspan="1" colspan="1"/>
                           <th rowspan="1" colspan="1">
                              <p>19</p>
                              <p>(5.9%)</p>
                           </th>
                           <th rowspan="1" colspan="1">
                              <p>84</p>
                              <p>(26%)</p>
                           </th>
                           <th rowspan="1" colspan="1">
                              <p>152</p>
                              <p>(47.1%)</p>
                           </th>
                           <th rowspan="1" colspan="1">
                              <p>49</p>
                              <p>(15.2%)</p>
                           </th>
                           <th rowspan="1" colspan="1">
                              <p>17</p>
                              <p>(5.3%)</p>
                           </th>
                           <th rowspan="1" colspan="1">
                              <p>2</p>
                              <p>(0.6%)</p>
                           </th>
                        </tr>
                     </tbody>
                  </table>
                  <table-wrap-foot>
                     <p>IGK: inhaled glucocorticoid, ALR: antilevkotrien, LABA: long-lasting beta2 agonyst, LAMA: long-lasting antiholinergic, OGC: oral glucocorticoid</p>
                  </table-wrap-foot>
               </table-wrap>
            </sec>
         </sec>
         <sec id="sl-s3" sec-type="Results">
            <label>3</label>
            <title>Results</title>
            <p>The analysed sample included 323 asthma patients who visited pneumatology clinics between 27 December 2017 and 30 April 2018. Of these, 114 (35.3%) patients were men, and 209 (64.7%) were women. The median age of all the patients was 56.8 years. Before joining the study, the patients had asthma for an average of 13.4 years. 48 of the participants were smokers, while 275 of them were non-smokers or former smokers (<xref ref-type="table" rid="sl-table2">Table 2</xref>). 222 patients (68.7%) had normal pulmonary functions, while with 101 patients (31.3%) an obstruction on the respiratory tract was measured with a spirometer, so another spirometry was conducted after a bronchodilator test. After the bronchodilator test the pulmonary function was normalized for 19 patients (5.8%). With 82 patients (25.3%) the obstruction was partially reversible (a positive bronchodilator test) or irreversible (<xref ref-type="fig" rid="sl-fig1">Figure 1</xref>). Of the medications, 300 patients (92.9%) used controllers, while 23 patients (7.1%) were without one. 19 patients (5.9%) did not use any other therapy except for a controller. 84 patients (26.0%) used single-tier therapy, 152 (47.1%) used 2-tier therapy, 49 (15.2%) used 3-tier therapy, 17 (5.3%) used 4-tier therapy, while 2 patients (0.6%) used 5-tier therapy. None of them used biological medications (<xref ref-type="table" rid="sl-table3">Table 3</xref>).</p>
            <p>207 patients (64.1%) had a self-treatment plan, while 208 (64.4%) understood the function of controller and preventer medication, 172 (53.3%) took their medications regularly, 117 (36.2%) occasionally, and 34 patients (10.4%) did not take medications at all. 160 patients (49.5%) demonstrated a proper technique of using the inhaler, 109 patients (33.7%) demonstrated an acceptable technique, and 54 patients (16.7%) a poor one. According to the specialist 240 patients (74.3%) had an appropriate therapy prescribed, while 83 patients (25.7%) did not (<xref ref-type="table" rid="sl-table4">Table 4</xref>).</p>
            <p>Comorbidities that could significantly affect how controlled asthma is, were present with 227 patients (70.3%), while 96 patients (29.7%) did not have any such diseases. Among comorbidities, obesity was prevalent with 108 patients (33.4%), chronic rhinosinusitis with 93 patients (28.8%), and GERD with 72 patients (22.3%) (<xref ref-type="table" rid="sl-table5">Table 5</xref>). 114 patients (36.8%) had two or more comorbidities (<xref ref-type="fig" rid="sl-fig2">Figure 2</xref>).</p>
            <fig position="anchor" id="sl-fig2" orientation="portrait">
               <label>Figure 2:</label>
               <caption>
                  <p> Distribution of the number of comorbidities</p>
               </caption>
               <p>
                  <graphic xlink:href="2904-en-web-resources/image/zdravvestn-2904-en-02.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
            <p>180 patients (55.7%) had specific triggers for uncontrolled asthma present, while 143 patients (44.3%) were not exposed to such triggers. 98 patients were exposed to allergens (54.4% of all exposed), 81 patients were exposed to medication (45.0% of all exposed) and 29 patients were exposed to smoking in their environment (16.1% of all exposed). Of the patients exposed to specific triggers, 152 (84.4% of all exposed) had 1 specific trigger present, and 28 (15.6% of all exposed) had 2 specific triggers present (<xref ref-type="table" rid="sl-table6">Table 6</xref>). Among medications that could affect uncontrolled asthma, ACE inhibitors (44.2%) and beta-receptor blockers (24.7%) were the most prevalent.</p>
            <table-wrap position="anchor" id="sl-table4" orientation="portrait">
               <label>Table 4:</label>
               <caption>
                  <p> Self-management plans, subjective factors, suitability of treatment.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Does the patient have a self-management plan?</td>
                        <td colspan="2" rowspan="1">
                           <p>Yes</p>
                           <p>207</p>
                           <p>(64.1%)</p>
                        </td>
                        <td colspan="2" rowspan="1">
                           <p>No</p>
                           <p>116</p>
                           <p>(35.9%)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Do you find that the patient understands the role of controlling and preventing medications for treating asthma?</td>
                        <td colspan="2" rowspan="1">
                           <p>YES</p>
                           <p>208</p>
                           <p>(64.4%)</p>
                        </td>
                        <td colspan="2" rowspan="1">
                           <p>NO</p>
                           <p>115</p>
                           <p>(35.6%)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Do you find that the patient takes their medication regularly (issued medications and actual use)?</td>
                        <td rowspan="1" colspan="1">
                           <p>Regularly</p>
                           <p>172</p>
                           <p>(53.3%)</p>
                        </td>
                        <td colspan="2" rowspan="1">
                           <p>Occasionally</p>
                           <p>117</p>
                           <p>(36.2%)</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>Does not take</p>
                           <p>34</p>
                           <p>(10.5%)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Is the patient able to show the correct technique of inhaling their medications.</td>
                        <td rowspan="1" colspan="1">
                           <p>Yes</p>
                           <p>160</p>
                           <p>(49.5%)</p>
                        </td>
                        <td colspan="2" rowspan="1">
                           <p>Acceptable</p>
                           <p>109</p>
                           <p>(33.7%)</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>Poor</p>
                           <p>54</p>
                           <p>(16.7%)</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">In your opinion, does the patient have an appropriate prescribed therapy for treating asthma?</td>
                        <td colspan="2" rowspan="1">
                           <p>YES</p>
                           <p>240</p>
                           <p>(74.3%)</p>
                        </td>
                        <td colspan="2" rowspan="1">
                           <p>NO</p>
                           <p>83</p>
                           <p>(25.7%)</p>
                        </td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>228 patients (70.6%) did not suffer from any exacerbation to their asthma in the past year, while 95 patients (29.4%) had one or more severe exacerbations in the past year (<xref ref-type="fig" rid="sl-fig3">Figure 3</xref>). A logistic regression analysis showed that the potential for a severe asthma exacerbation in the past year was about 2.6-times higher in the group of patients who do not understand the role of the controller and preventive medications for treating asthma (95% IZ: [1.4; 4.8]; p = 0019), compared to those who understand the role of these medications, and about 2.4-times higher for those patients who do not have a self-treatment plan than for those who have one (95% IZ: [1.3; 4.3]; p = 0.042).</p>
            <table-wrap position="anchor" id="sl-table5" orientation="portrait">
               <label>Table 5:</label>
               <caption>
                  <p> Comorbidities that could significantly affect how controlled the asthma is.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Disease</th>
                        <th rowspan="1" colspan="1">Number of patients</th>
                        <th rowspan="1" colspan="1">%</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Obesity</td>
                        <td rowspan="1" colspan="1">108</td>
                        <td rowspan="1" colspan="1">33.4%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Rinosinusitis</td>
                        <td rowspan="1" colspan="1">93</td>
                        <td rowspan="1" colspan="1">28.8%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Gastroesophageal reflux disease (GERD)</td>
                        <td rowspan="1" colspan="1">72</td>
                        <td rowspan="1" colspan="1">22.3%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Depression/anxiety</td>
                        <td rowspan="1" colspan="1">31</td>
                        <td rowspan="1" colspan="1">9.6%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Obstructive sleep apnea</td>
                        <td rowspan="1" colspan="1">11</td>
                        <td rowspan="1" colspan="1">3.4%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Nutritive allergy</td>
                        <td rowspan="1" colspan="1">7</td>
                        <td rowspan="1" colspan="1">2.2%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Other</td>
                        <td rowspan="1" colspan="1">59</td>
                        <td rowspan="1" colspan="1">18.3%</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>According to the physicians’ assessments, 74 patients (22.9%) from the sample suffered from severe asthma according to GINA criteria, while 249 patients (77.1%) did not have severe asthma.</p>
            <table-wrap position="anchor" id="sl-table6" orientation="portrait">
               <label>Table 6:</label>
               <caption>
                  <p> Presence of specific triggers for uncontrolled asthma.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Trigger</th>
                        <th rowspan="1" colspan="1">Number of patients</th>
                        <th rowspan="1" colspan="1">% (n = 180)</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Allergens</td>
                        <td rowspan="1" colspan="1">71</td>
                        <td rowspan="1" colspan="1">39.4%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Medication</td>
                        <td rowspan="1" colspan="1">63</td>
                        <td rowspan="1" colspan="1">35.0%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Smoking</td>
                        <td rowspan="1" colspan="1">18</td>
                        <td rowspan="1" colspan="1">10.0%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Allergens + medication</td>
                        <td rowspan="1" colspan="1">17</td>
                        <td rowspan="1" colspan="1">9.4%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Allergens + smoking</td>
                        <td rowspan="1" colspan="1">10</td>
                        <td rowspan="1" colspan="1">5.6%</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Medication + smoking</td>
                        <td rowspan="1" colspan="1">1</td>
                        <td rowspan="1" colspan="1">0.6%</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
         </sec>
         <sec id="sl-s4" sec-type="Discussion">
            <label>4</label>
            <title>Discussion</title>
            <p>Asthma is treated by levels in 5 steps with regard to the current state of asthma control (<xref ref-type="bibr" rid="sl-b1">1</xref>). The level of asthma control is defined by clinical symptoms, while the severity of the disease is rated by the medications required for maintaining control (<xref ref-type="bibr" rid="sl-b7">7</xref>). The Gaining Optimal Asthma ControL (GOAL) study showed that levelled treatment and good patient adherence can achieve a good control of asthma with most patients <xref ref-type="bibr" rid="sl-b8">8</xref>, while observational studies have adversely shown that a large share of patients still have uncontrolled asthma (<xref ref-type="bibr" rid="sl-b2">2</xref>,<xref ref-type="bibr" rid="sl-b3">3</xref>). Uncontrolled asthma is linked to a large number of severe exacerbations, an accelerated decline of pulmonary function, a decreased quality of life, it lowers the patient’s productivity and increases the costs of treating the disease (<xref ref-type="bibr" rid="sl-b9">9</xref>).</p>
            <fig position="anchor" id="sl-fig3" orientation="portrait">
               <label>Figure 3:</label>
               <caption>
                  <p> Number of severe exacerbations in the past year.</p>
               </caption>
               <p>
                  <graphic xlink:href="2904-en-web-resources/image/zdravvestn-2904-en-03.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
            <p>Our study included adult patients of all ages, who had been in treatment for asthma for at least one year. 68.7% of all the participating patients with uncontrolled asthma still had a normal pulmonary function, which is a good indication for future course of the disease. With others we discovered an obstructive ventilation disorder through spirometry, and for 5.8% of patients it was completely resolved after inhaling bronchodilator. The group of patients with such an obstruction in the respiratory tract shows the need for scaling up the levelled asthma treatment to the next phase. With 24.3% patients the obstruction on the respiratory tract was partially reversible (a positive bronchodilator test) or irreversible. Some of the patients from this group have severe asthma and an inflammatory airway, which may result in a permanent obstruction. Others are patients who may not have received sufficient doses of controlling medications, either because the prescribed dosage of controlling medication was too low, or because of a poor technique of using the inhaler or adherence.  Regular and correct treatment with inhaled glucocorticoids (IGK) can sufficiently improve FEV<sub>1</sub> in a few days and plateaus in about 2 months (<xref ref-type="bibr" rid="sl-b10">10</xref>). It is possible that this group also includes some patients with other chronic pulmonary diseases, such as KOPB and chronic bronchiolitis.</p>
            <p>In literature the most frequently listed main reasons for uncontrolled asthma are poor patient adherence and mistakes in the use of inhaler (<xref ref-type="bibr" rid="sl-b11">11</xref>). 53.3% of patients participating in our study took their medications regularly. Assessing adherence based on the difference between medications issued and medications used, as taken from the electronic prescription database, is a rough method that often overestimates medication adherence. In clinical studies the most often used method is inspecting returned inhalers for the amounts of medication used, or the inhaler’s weight. Recently, inhalers with electronic counters have become available, which log the time of activation and the efficacy of the inhaler application. The low share of patients (16.7%) with a poor technique of using the inhaler is encouraging. In the past few years we created good conditions in Slovenia for the patients to learn the correct inhaler use technique, both in specialist clinics and in primary level reference clinics. The inhaler usage technique must be consistently checked during control examinations (<xref ref-type="bibr" rid="sl-b12">12</xref>). The most frequent factor that can be related to uncontrolled asthma in our study were comorbidities, especially obesity, rhinosinusitis and GERD. Lowering one’s body weight improves asthma control, the pulmonary functions, the quality of life and the consumption of medication (<xref ref-type="bibr" rid="sl-b13">13</xref>). The connection between the upper and lower respiratory tract in asthma has been recognized for a long time. Treating a comorbid allergic rhinitis or a chronic rhinosinusitis, especially when it is connected with nasal polyposis, improves asthma control (<xref ref-type="bibr" rid="sl-b14">14</xref>). Most epidemiology studies show that at least 80% of asthma patients also have a nasal disease (<xref ref-type="bibr" rid="sl-b1">1</xref>).  After a professional assessment by our specialists we discovered chronic rhinosinusitis as a significant potential risk factor for uncontrolled asthma with only 28.8% of patients. This group especially included patients with frequent or constant nasal symptoms, for whom therapy with medications and/or surgery was not successful enough. Treatment of patients with asthma and GERD with a proton pump inhibitor is especially successful with those patients with clear GERD symptoms and paroxysmal nocturnal dyspnoea symptoms (<xref ref-type="bibr" rid="sl-b15">15</xref>). For more than a half of patients the presence of specific triggers was a factor that may be related to uncontrolled asthma. The main factors in this group are medications (mostly ACE inhibitors), exposure to allergens, and in a lesser scope also smoking. Even though Slovenian and international GINA guidelines list ACE inhibitors among medications that could pose a risk for uncontrolled asthma, there is no direct proof for this in literature. In a smaller share of asthma patients, ACE inhibitors may cause coughing, and should therefore not be administered any more. The study included adult patients of all ages. With age the number of comorbidities for asthma patients increases, and with this also the need to treat them. Checking the medications that an asthma patient constantly takes to treat comorbidities, and replacing them with safer options where possible, is a necessary measure for good asthma control. Allergens in the home or work environment can be completely or partially avoided. A patient with mild or moderate asthma can be treated with specific immunotherapy. Smoking decreases the efficiency of medicating with inhaled glucocorticoids, so patients must be encouraged to quit smoking (<xref ref-type="bibr" rid="sl-b1">1</xref>).</p>
            <p>Uncontrolled asthma increases the risk for exacerbation in and of itself (<xref ref-type="bibr" rid="sl-b16">16</xref>). Other significant factors for exacerbation that are unrelated to the level of asthma control include: one or several exacerbations in the past year, poor adherence, incorrect inhaler use, chronic rhinosinusitis and smoking (<xref ref-type="bibr" rid="sl-b17">17</xref>). In our sample of patients with uncontrolled asthma fewer than 30% of them suffered from one or more severe exacerbations. Regression analysis showed that the most important factors related to severe exacerbations in the past year are: not understanding the role of preventive and controller medications and if the physician did not issue a plan for asthma self-management. Understanding the role of asthma medications is one of key elements for obtaining the asthma control. It must be included in the medical training of the physician and the nurse who treat the patient (<xref ref-type="bibr" rid="sl-b1">1</xref>). Teaching asthma self-management includes 3 components: the patient’s assessment of symptoms and the maximum air flow at exhalation, written instructions for regular management, recognizing and taking action at an asthma exacerbation, and regular check-ups of asthma control, how the management is going and assessment of the correct inhaler use (<xref ref-type="bibr" rid="sl-b18">18</xref>). All asthma patients should receive asthma self-management training.</p>
            <p>Uncontrolled asthma is not a synonym for severe asthma. By removing factors that can cause uncontrolled asthma most patients can bring their asthma under control. The reason for severe asthma is not in the above factors for uncontrolled asthma, but in the nature of the disease. There is not much data on the global prevalence of severe asthma. Experts estimate that about 5–10% of asthma patients have severe asthma (<xref ref-type="bibr" rid="sl-b4">4</xref>). According to the Dutch observational study this number is even lower at 4.5%. In our study the estimated share of severe asthma in the sample of adult patients with uncontrolled asthma is 22.9%. Taking into account the 38% prevalence of uncontrolled asthma in Slovenia, as discovered in the previous study, the share of severe asthma patients in Slovenia is at least 8%.</p>
            <p>Even though the study was conducted on a select population of patients with uncontrolled asthma in outpatient pulmonary clinics, we believe that the sample is representative, as the selected clinics were equally distributed across Slovenia. The study included both the patients who had been treated in specialist clinics for a while, as well as those who were referred there from the primary care level because of uncontrolled asthma. Family physicians most often refer patients with uncontrolled asthma to a specialist. Naturally, this means that a potential smaller share of patients with uncontrolled asthma treated at the primary level was not included. The study was conducted in the winter and the spring, when the rate of respiratory tract infections is the highest. Patients who suffered from an asthma exacerbation or a respiratory infection in the past month, were not included in the study. A major advantage of the study is a comprehensive assessment of risk factors for uncontrolled asthma. Besides assessing adherence and the inhaler application technique, which are most often used in studies, we also added comorbidities and specific triggers.</p>
            <p>The weaknesses of this study include the possibility of an incorrect subjective professional assessment by the specialist, especially when assessing the correctness of inhaler application technique, assessing specific triggers for uncontrolled asthma, and assessing the suitability of current therapy for asthma treatment.</p>
         </sec>
         <sec id="sl-s5" sec-type="Conclusion">
            <label>5</label>
            <title>Conclusion</title>
            <p>Our study confirmed that from the sample of adult patients at out-patient pulmonary clinics across Slovenia the most frequent factors related to uncontrolled asthma are comorbidities, specific triggers and poor patient adherence. A third of patients with uncontrolled asthma still have at least one severe exacerbation per year in spite of treatment. Not understanding the role of medications and the absence of an individualized self-management plan are the most significant reasons for severe exacerbations. In the future asthma patients will have to be trained better and for each one an individualized asthma self-management plan will have to be prepared.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="sl-b1">
               <mixed-citation publication-type="webpage">
                    <article-title>Global Strategy for Asthma Management and Prevention</article-title>.
                    <year>2018</year>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2018-08-25">cited 2018 Aug 25</date-in-citation>]. 
                    <comment>Available from:<uri>https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdfi</uri>
                  </comment>. 
                </mixed-citation>
            </ref>
            <ref id="sl-b2">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Price</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fletcher</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>van der Molen</surname>
                        <given-names>T</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey</article-title>. 
                    <source>NPJ Prim Care Respir Med</source>. 
                    <year>2014</year>
                    <month>Jun</month>;
                    <volume>24</volume>(
                    <issue>1</issue>):
                    <fpage>14009</fpage>. 
                    <pub-id pub-id-type="doi">10.1038/npjpcrm.2014.9</pub-id>
                    <pub-id pub-id-type="pmid">24921985</pub-id>
                    <issn>2055-1010</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b3">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Janežič</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Locatelli</surname>
                        <given-names>I</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kos</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>44th ESCP International Symposium on Clinical Pharmacy Medicines Information: Making Better Decisions : Lisbon, Portugal, 28-30 October 2015</article-title>. 
                    <source>Int J Clin Pharm</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>38</volume>(
                    <issue>2</issue>):
                    <fpage>470</fpage>–
                    <lpage>598</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s11096-015-0240-y</pub-id>
                    <pub-id pub-id-type="pmid">26739129</pub-id>
                    <issn>2210-7703</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b4">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Chung</surname>
                        <given-names>KF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wenzel</surname>
                        <given-names>SE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Brozek</surname>
                        <given-names>JL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bush</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Castro</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sterk</surname>
                        <given-names>PJ</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma</article-title>. 
                    <source>Eur Respir J</source>. 
                    <year>2014</year>
                    <month>Feb</month>;
                    <volume>43</volume>(
                    <issue>2</issue>):
                    <fpage>343</fpage>–
                    <lpage>73</lpage>. 
                    <pub-id pub-id-type="doi">10.1183/09031936.00202013</pub-id>
                    <pub-id pub-id-type="pmid">24337046</pub-id>
                    <issn>0903-1936</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b5">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Škrgat</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Triller</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Košnik</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Poplas Susič</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Petek</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vodopivec Jamšek</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Priporočila za obravnavo bolnika z astmo na primarni in specialistični pulmološki ravni v Sloveniji</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2016</year>;
                    <volume>85</volume>(
                    <issue>11/12</issue>):
                    <fpage>693</fpage>–
                    <lpage>706</lpage>.
                    <pub-id pub-id-type="doi">10.6016/ZdravVestn.2470</pub-id>
                    <issn>0350-0063</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b6">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Terl</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sedlák</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cap</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Dvořáková</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kašák</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kočí</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy</article-title>. 
                    <source>Allergy</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>72</volume>(
                    <issue>9</issue>):
                    <fpage>1279</fpage>–
                    <lpage>87</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/all.13165</pub-id>
                    <pub-id pub-id-type="pmid">28328094</pub-id>
                    <issn>0105-4538</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b7">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Taylor</surname>
                        <given-names>DR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bateman</surname>
                        <given-names>ED</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Boulet</surname>
                        <given-names>LP</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Boushey</surname>
                        <given-names>HA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Busse</surname>
                        <given-names>WW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Casale</surname>
                        <given-names>TB</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A new perspective on concepts of asthma severity and control</article-title>. 
                    <source>Eur Respir J</source>. 
                    <year>2008</year>
                    <month>Sep</month>;
                    <volume>32</volume>(
                    <issue>3</issue>):
                    <fpage>545</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1183/09031936.00155307</pub-id>
                    <pub-id pub-id-type="pmid">18757695</pub-id>
                    <issn>0903-1936</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b8">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Bateman</surname>
                        <given-names>ED</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Boushey</surname>
                        <given-names>HA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bousquet</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Busse</surname>
                        <given-names>WW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Clark</surname>
                        <given-names>TJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Pauwels</surname>
                        <given-names>RA</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>GOAL Investigators Group</collab>
                    </person-group>. 
                    <article-title>Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study</article-title>. 
                    <source>Am J Respir Crit Care Med</source>. 
                    <year>2004</year>
                    <month>Oct</month>;
                    <volume>170</volume>(
                    <issue>8</issue>):
                    <fpage>836</fpage>–
                    <lpage>44</lpage>. 
                    <pub-id pub-id-type="doi">10.1164/rccm.200401-033OC</pub-id>
                    <pub-id pub-id-type="pmid">15256389</pub-id>
                    <issn>1073-449X</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b9">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Demoly</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Annunziata</surname>
                        <given-names>K</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Gubba</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Adamek</surname>
                        <given-names>L</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years</article-title>. 
                    <source>Eur Respir Rev</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>21</volume>(
                    <issue>123</issue>):
                    <fpage>66</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1183/09059180.00008111</pub-id>
                    <pub-id pub-id-type="pmid">22379176</pub-id>
                    <issn>0905-9180</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b10">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Reddel</surname>
                        <given-names>HK</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jenkins</surname>
                        <given-names>CR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Marks</surname>
                        <given-names>GB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ware</surname>
                        <given-names>SI</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Xuan</surname>
                        <given-names>W</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Salome</surname>
                        <given-names>CM</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Optimal asthma control, starting with high doses of inhaled budesonide</article-title>. 
                    <source>Eur Respir J</source>. 
                    <year>2000</year>
                    <month>Aug</month>;
                    <volume>16</volume>(
                    <issue>2</issue>):
                    <fpage>226</fpage>–
                    <lpage>35</lpage>. 
                    <pub-id pub-id-type="doi">10.1034/j.1399-3003.2000.16b08.x</pub-id>
                    <pub-id pub-id-type="pmid">10968496</pub-id>
                    <issn>0903-1936</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b11">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Haughney</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Price</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kaplan</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Chrystyn</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Horne</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>May</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Achieving asthma control in practice: understanding the reasons for poor control</article-title>. 
                    <source>Respir Med</source>. 
                    <year>2008</year>
                    <month>Dec</month>;
                    <volume>102</volume>(
                    <issue>12</issue>):
                    <fpage>1681</fpage>–
                    <lpage>93</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.rmed.2008.08.003</pub-id>
                    <pub-id pub-id-type="pmid">18815019</pub-id>
                    <issn>0954-6111</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b12">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Košnik</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Triller</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Šelb</surname>
                        <given-names>J</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Mnenje pulmologov o pomenu vdihovalnikov pri bolnikih z astmo ali KOPB</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2017</year>;
                    <volume>86</volume>(
                    <issue>3-4</issue>):
                    <fpage>105</fpage>–
                    <lpage>14</lpage>.
                    <pub-id pub-id-type="doi">10.6016/ZdravVestn.2472</pub-id>
                    <issn>0350-0063</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b13">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Adeniyl</surname>
                        <given-names>FB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Young</surname>
                        <given-names>T</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Weight loss intervention for chronic asthma</article-title>. 
                    <source>Cochrane Database Syst Rev</source>. 
                    <year>2012</year>;
                    <volume>7</volume>:
                    <fpage>CD009339</fpage>.
                    <issn>1469-493X</issn>
                    <pub-id pub-id-type="doi">10.1002/14651858.CD009339.pub2</pub-id>
                    <pub-id pub-id-type="pmid">22786526</pub-id>
                    <issn>1469-493X</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b14">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Bousquet</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Schünemann</surname>
                        <given-names>HJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Samolinski</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Demoly</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Baena-Cagnani</surname>
                        <given-names>CE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bachert</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>World Health Organization Collaborating Center for Asthma and Rhinitis</collab>
                    </person-group>. 
                    <article-title>Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs</article-title>. 
                    <source>J Allergy Clin Immunol</source>. 
                    <year>2012</year>
                    <month>Nov</month>;
                    <volume>130</volume>(
                    <issue>5</issue>):
                    <fpage>1049</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jaci.2012.07.053</pub-id>
                    <pub-id pub-id-type="pmid">23040884</pub-id>
                    <issn>0091-6749</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b15">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sopo</surname>
                        <given-names>SM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Radzik</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Calvani</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Does treatment with proton pump inhibitors for GERD improve asthma symptoms in children with asthma and GERD? A systematic revie</article-title>. 
                    <source>J Investig Allergol Clin Immunol</source>. 
                    <year>2009</year>;
                    <volume>19</volume>(
                    <issue>1</issue>):
                    <fpage>1</fpage>–
                    <lpage>5</lpage>.
                    <pub-id pub-id-type="pmid">19274922</pub-id>
                    <issn>1018-9068</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b16">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Meltzer</surname>
                        <given-names>EO</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Busse</surname>
                        <given-names>WW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wenzel</surname>
                        <given-names>SE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Belozeroff</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Weng</surname>
                        <given-names>HH</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Feng</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation</article-title>. 
                    <source>J Allergy Clin Immunol</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>127</volume>(
                    <issue>1</issue>):
                    <fpage>167</fpage>–
                    <lpage>72</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jaci.2010.08.042</pub-id>
                    <pub-id pub-id-type="pmid">21093024</pub-id>
                    <issn>0091-6749</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b17">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Loymans</surname>
                        <given-names>RJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Honkoop</surname>
                        <given-names>PJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Termeer</surname>
                        <given-names>EH</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Snoeck-Stroband</surname>
                        <given-names>JB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Assendelft</surname>
                        <given-names>WJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Schermer</surname>
                        <given-names>TR</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model</article-title>. 
                    <source>Thorax</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>71</volume>(
                    <issue>9</issue>):
                    <fpage>838</fpage>–
                    <lpage>46</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-208138</pub-id>
                    <pub-id pub-id-type="pmid">27044486</pub-id>
                    <issn>0040-6376</issn>
                </mixed-citation>
            </ref>
            <ref id="sl-b18">
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Gibson</surname>
                        <given-names>PG</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Powell</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Coughlan</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wilson</surname>
                        <given-names>AJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Abramson</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Haywood</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Self-management education and regular practitioner review for adults with asthma</article-title>. 
                    <source>Cochrane Database Syst Rev</source>. 
                    <year>2003</year>;(
                    <issue>1</issue>):
                    <fpage>CD001117</fpage>.
                    <pub-id pub-id-type="pmid">12535399</pub-id>
                    <issn>1469-493X</issn>
                </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
